Back to search

A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update

A. van Oosterom, Peter Reichardt, Jean‐Yves Blay, Herlinde Dumez, Jonathan A. Fletcher
DOI: 10.1200/jco.2005.23.16_suppl.9033
Journal of Clinical Oncology

Data up to Jan 2025

Published2005
Citations46
References0
Fields
MedicineGastroenterologyInternal medicine

Total Citations Per Year

Abstract

References (0)

No references found

Cited By (0)

No citing papers found in database

A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM)… (2005) – Journal of Clinical Oncology | Metascience Observatory Explorer